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BY-NC-ND license (http://creativecomAbstract Background/purpose: The aim of this study is to investigate the role of tigecycline
in Vibrio vulnificus infection.
Methods: Eight randomly selected clinical V. vulnificus isolates were studied to obtain the min-
imal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the
timeekill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse
model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotax-
ime in combination with minocycline or tigecycline.
Results: The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus iso-
lates was 0.06e0.12 mg/mL, 0.03e0.06 mg/mL, and 0.03e0.06 mg/mL, respectively. In time
ekilling studies, at the concentration of 1  MIC, the inhibitory effect of tigecycline persisted
for 24 hours in five of eight isolates. With 2  MIC and trough level, the inhibitory effect was
noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and ti-
gecycline plus cefotaxime at 1/2  MIC, the bactericidal effect was noted in 25% and 62.5% of
eight isolates and synergism in 50% and 75% of isolates. With a low (1.25  105 CFU/mL) inoc-
ulum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or mino-
cycline plus cefotaxime on the 14th day. At the inoculum of 1.25  106 CFU, the survival rateof Medical Research, Chi Mei Medical Center, Number 901, Chung-Hwa Road, Yung-Kang City, 710
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Journal of Microbiology, Immunologywas 33.3% on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the
mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3% vs. 0%,
p Z 0.01 by Fisher’s exact test).
Conclusion: Our in vitro combination and animal studies indicate that tigecycline could be an
option for the treatment of invasive V. vulnificus infections.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Vibrio vulnificus is primarily associated with severe,
distinctive septicemia and soft tissue infection, including
necrotizing fasciitis, or both, especially in patients with
malignancy, adrenal insufficiency, liver cirrhosis, or dia-
betes.1e5 The clinical courses of septicemic patients with V.
vulnificus are often rapidly progressing, and more than 50%
of such patients die within 48 hours of hospitalization.6 Our
previous study showed that cefotaxime combined with
minocycline was in vitro active against V. vulnificus, and
was effective in a mouse model.7 Clinical experiences also
support the use of minocycline plus cefotaxime for severe
V. vulnificus infections.6,8
According to previous in vitro studies, tigecycline, a
member of a new class of glycylcycline, exhibits good tissue
penetration and has been reported to be active againstVibrio
species, making it a potential choice for invasive human
Vibrio infections.9,10 Successful tigecycline salvage therapy
for V. vulnificus necrotizing fasciitis in a child was reported
recently.11 Because of the lack of parenteral preparation of
minocycline in Taiwan, we decided to study the role of tige-
cycline in the treatment of V. vulnificus infection. Moreover,
as severe V. vulnificus infections often occurred in immuno-
compromised patients, it is important to initiate broad
spectrum antibiotics, such as cefotaxime plus tigecycline, to
cover many potential pathogens for severe infectious dis-
eases. Therefore, we examined in vitro killing effect of
tigecycline and initiated in vivo survival studies to evaluate
the efficacy of tigecycline alone or in combination with
cefotaxime in treatment of murine V. vulnificus infections.
Methods
Bacterial isolates
Eight clinical V. vulnificus isolates were randomly selected
from Chi Mei Medical Center in southern Taiwan. The iso-
lates were stored at 80C in Protect Bacterial Preservers
(Technical Service Consultants Ltd., Heywood, UK) prior to
use. Species confirmation was performed using standard
biochemical methods, via a VITEK 2 automated system
(bioMe´rieux, Marcy l’Etoile, France).
Antibiotics and minimal inhibitory concentrations
The minimal inhibitory concentrations (MICs) of ampicillin,
cefazolin, cefotaxime, ceftriaxone, ciprofloxacin, genta-
micin, minocycline (Sigma, St. Louis, MO, USA), tigecyclineang H-J, et al., In vitro and in v
and Infection (2016), http://dx.(Pfizer, New York, NY, USA), and imipenem (U.S. Pharmaco-
peia, Rockville, MD, USA), were determined by agar dilution
on MuellereHinton agar (Oxoid, Basingstoke, UK), according
to the Clinical and Laboratory Standards Institute (CLSI) rec-
ommendations. Interpretation criteria for susceptibility data
were based on CLSI and Food and Drug Administration guide-
lines.12,13 Inocula were prepared by suspending growth from
overnight cultures in saline to a turbidity of a 0.5 McFarland
standard. Inoculated plates were then incubated in ambient
air at 37C for 24 hours. Escherichia coli ATCC 25922 was
included as the control strain in each run. Tigecycline MICs
were measured by broth microdilution as recommended.12,14
The MuellereHinton broth with calcium (25 mg/mL) and
magnesium (12.5 mg/mL) (CAMHB) was freshly prepared.
Appropriate5 105 colony-formingunits (CFU)/mLwasmixed
with serial drug dilutions and incubated in ambient air at 35C
for 18e24 hours.
Timeekill studies of tigecycline
Timeekill studies for V. vulnificus isolates were performed
according to the CLSI-defined methodology.15 In brief,
bacterial suspensions were diluted to 5.0  105 CFU/mL in
25 mL fresh MuellereHinton broth. Drug concentrations of
tigecycline in the timeekill studies were adjusted to 1/
4  MIC, 1/2  MIC, 2  MIC, and serum trough level
(0.13 mg/mL). Bacterial counts were measured at 2 hours,
4 hours, 8 hours, 24 hours, and 48 hours by enumerating the
colonies in 10-fold serially diluted specimens of 100-mL al-
iquots plated on the nutrient agar (Difco Laboratories,
Sparks, MD, USA) at 37C.
In vitro antibacterial activity of antibiotic
combinations
The in vitro antibacterial activity of three antimicrobial
agents alone or in combination (tigecycline plus cefotax-
ime, and minocycline plus cefotaxime) was tested.
Approximately 1  106 CFU/mL V. vulnificus was used for
the combination test. Drug concentrations were adjusted to
1/2-fold of MICs. Bacterial counts were measured at
24 hours on nutrient agar (Difco Laboratories) at 37C.
Definitions
Synergy and antagonism were defined as 2 log10 greater
and lesser kills between the combination and the most
active constituent after 24 hours. Bacteriostatic activitiesivo antibacterial activity of tigecycline against Vibrio vulnificus,
doi.org/10.1016/j.jmii.2016.04.009
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activities were defined as 3 log10 reductions in CFU/mL at
24 hours, respectively, relative to the starting inoculum.16
All experiments were performed in duplicate.In vivo mouse study
Female inbred BALB/c mice (Animal Center, National Sci-
ence Council, Taipei, Taiwan) weighing 18e20 g (6e8 weeks
old) were used in this study. Vv14-3 was randomly selected
and incubated in MuellereHinton broth overnight and sub-
cultured. After 3 hours of incubation in sterile broth, the
pellet obtained after centrifugation was diluted to the
anticipated turbidity for mouse experiments. The dosage of
cefotaxime for mice is 150 mg/kg every 6 hours and mino-
cycline 20 mg/kg every 12 hours intraperitoneally admin-
istered,17 and tigecycline 6.25 mg/kg every 12 hours
subcutaneously administered as described previously.18
Antibiotics were initiated 2 hours after intraperitoneal
bacterial inoculation and administered for 48 hours. The
number of surviving mice was recorded at 8-hour intervals
for 120 hours.Pharmacokinetic studies
The dose of tigecycline, subcutaneous injection of 6.25 mg/
kg, was selected based on published pharmacokinetic data,
which indicated that this dose in mice can achieve a serum
maximum concentration (Cmax) of 1.17 mg/mL, similar to
the Cmax of 0.93 mg/mL achieved at the dose of 100 mg
every 12 hours in humans.9,19 At multiple time points of
0.25 hours, 0.5 hours, 1 hour, 2 hours, 3 hours, 5 hours,
7 hours, 9 hours, and 12 hours, blood and thigh muscle
samples were collected from six mice. Tigecycline con-
centrations were estimated using the paper-disk diffusion
method with a control strain, Bacillus cereus BCRC10446.
All samples were assayed in triplicate. The lower limit of
detection for tigecycline is 0.06 mg/mL.goL
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Data analysis was performed using SPSS 10.0 for Windows
(SPSS Inc., Chicago, IL, USA). To compare the effects be-
tween different treatment groups, two-way and one-way
within-repeated subjects analysis of variance tests were
applied. Fisher’s exact test was applied to compare the
survival rates between groups. A p value < 0.05 was
considered statistically significant.Time (h)
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Figure 1. Timeekill curves of eight clinical Vibrio vulnificus
isolates incubated with different concentrations of tigecycline.
MIC Z minimal inhibitory concentration.Results
We tested the biotyping of these V. vulnificus isolates in our
study and found that all tested isolates are Biotype 1 (data
not shown). The MIC50 of tigecycline, cefotaxime, and
minocycline for eight randomly selected V. vulnificus iso-
lates was 0.03 mg/mL, 0.06 mg/mL, and 0.12 mg/mL,
respectively.Please cite this article in press as: Tang H-J, et al., In vitro and in v
Journal of Microbiology, Immunology and Infection (2016), http://dx.Timeekill studies of tigecycline
The timeekill studies of eight V. vulnificus isolates cocul-
tured with tigecycline at the concentrations of 1/2  MIC,
1  MIC, 2  MIC, and 0.13 mg/mL (serum trough level) are
shown in Figure 1. When V. vulnificus isolates at an inoc-
ulum of 5  105 CFU/mL were incubated with tigecycline at
the concentration of 1/2  MIC (0.03 mg/mL), the bacterial
load increased to 108 CFU/mL at 24 hours. At the tigecy-
cline concentration of 1  MIC (0.06 mg/mL), V. vulnificus
was temporarily inhibited at 8 hours, but regrew later
(Figure 1). At a higher concentration of 2  MIC (0.12 mg/
mL), bacterial growth was inhibited until 48 hours, and
bactericidal activity was evident at 24 hours. At the con-
centration of 0.13 mg/mL, the result can be expected to be
similar to that of 0.12 mg/mL.
Among the V. vulnificus isolates tested, the isolate
numbers with a decrease of at least 1 log10 CFU/mL, 2
log10 CFU/mL, or 3 log10 CFU/mL at different incubation
times and tigecycline concentrations are shown in Table 1.
Of note, tigecycline at the concentration of 2  MIC and
serum trough level, can exhibit bactericidal activity at
24 hours.
In vitro antibacterial activity of antibiotic
combinations
With the combination of minocycline plus cefotaxime, both
at the concentration of 1/2  MIC, the colony count
decreased from 0 log10 to 4.26 log10 compared with the
starting inoculum, and such a combination was bactericidal
to two (25%) of eight isolates (Figure 2). With the same
concentration combination, the colony count decreased
from 0.98 log10 to 4.78 log10 compared with the most active
drug. Such a combination regimen was shown to be syner-
gistic against four (50%) isolates. By contrast, the combi-
nation of tigecycline plus cefotaxime can decrease the
bacterial load from 2.2 log10 to 3.9 log 10 compared with
starting inoculum, and be bactericidal to five (62.5%) iso-
lates and synergistic against six (75%) isolates.ivo antibacterial activity of tigecycline against Vibrio vulnificus,
doi.org/10.1016/j.jmii.2016.04.009
Table 1 Isolate numbers of eight clinical Vibrio vulnificus strains with a decline of 1, 2, or 3 log10 CFU/mL at different
incubation time, with tigecycline at the concentrations of 1/2  MIC, 1  MIC, 2  MIC, and 0.13 mg/mL (the serum trough level,
if standard doses of tigecycline are intravenously given).
Drug level No. of isolates with a specific decline of bacterial load
2 h 4 h 8 h 24 h
1
log10
2
log10
3
log10
1
log10
2
log10
3
log10
1
log10
2
log10
3
log10
1
log10
2
log10
3
log10
1/2  MIC 1 0 0 2 0 0 0 0 0 0 0 0
1  MIC 3 2 1 1 4 3 0 0 8 2 1 5
2  MIC 1 3 4 0 1 7 0 0 8 0 0 8
0.13 mg/mL 0 4 4 0 1 7 0 0 8 0 0 8
MIC Z minimal inhibitory concentration.
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Figure 2. In vitro combination effect of 1/2  MIC of minocycline (MNO) or tigecycline (TGC) and 1/2  MIC of cefotaxime (CTX)
for eight clinical Vibrio vulnificus isolates after 24 hours of incubation. MIC Z minimal inhibitory concentration.
Table 2 Survival rates of mice infected by a clinical
isolate of Vibrio vulnificus, Vv14-3, at a low or high inoc-
ulum and treated by tigecycline (TGC) alone, tigecycline
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After blood and muscle of thigh samples were collected
from six mice, the serum Cmax of tigecycline was 0.98 mg/
mL in average, and thigh tissue Cmax was 1.65 mg/mL.plus cefotaxime (CTX), or minocycline (MNO) plus
cefotaxime.
Antibiotic regimens Survival rate (%)
Day 0 Day 1 Day 2 Days
3e5
Day 14
Low inoculum (1.25  105 CFU)
Control, n Z 10 100 0 0 0 0
TGC, n Z 10 100 100 100 100 100
TGC þ CTX, n Z 10 100 100 100 100 100
MNO þ CTX, n Z 10 100 100 100 100 100
High inoculum (1.25  106 CFU)
Control, n Z 12 100 0 0 0 0
TGC, n Z 12 100 0 0 0 0
TGC þ CTX, n Z 12 100 33.3 33.3 33.3 33.3
MNO þ CTX, n Z 12 100 0 0 0 0Survival rates of mice with V. vulnificus peritonitis
The survival rates of mice infected by Vv14-3 with a low
(1.25  105 CFU/mL) and high inoculum (1.25  106 CFU/
mL) and treated by tigecycline alone, or tigecycline or
minocycline plus cefotaxime are shown in Table 2. In the
low inoculum group, all mice treated by either tigecycline
alone, tigecycline plus cefotaxime, or minocycline plus
cefotaxime survived for 14 days. However, with a high
inoculum, all mice died, except the mice in the tigecycline
plus cefotaxime group, which had a survival rate of 33.3%.
Such an outcome was significant between the former group
and two other treatment groups (i.e., mice treated by
tigecycline alone or minocycline plus cefotaxime) (33.3%
vs. 0%; p Z 0.01 by Fisher’s exact test).Please cite this article in press as: Tang H-J, et al., In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus,
Journal of Microbiology, Immunology and Infection (2016), http://dx.doi.org/10.1016/j.jmii.2016.04.009
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In the present study, the potent antibacterial activity and
rapid bactericidal effect of tigecycline against V. vulnificus
were observed, because the bacterial load can be
decreased at least 3 log10 at 2 hours in 50% of eight clinical
isolates. The MIC of V. vulnificus to tigecycline was 0.03 mg/
mL or 0.06 mg/mL, and the tigecycline concentration we
tested was 1  MIC or 2  MIC, which is close to the serum
trough level, 0.13 mg/mL.9,18,19 This indicates that tigecy-
cline could be bactericidal for V. vulnificus.
By contrast, in timeekill assays tigecycline alone and in
combination with other antibiotics often showed bacterio-
static effect against enterococci, Gram-negative bacilli
including carbapenem-susceptible and carbapenem-
resistant Acinetobacter baumannii, extended-spectrum
beta-lactamase (ESBL)-producing E. coli, or Klebsiella
pneumoniae carbapenemase-producing Enterobacteriaceae
strains.20e24 However, the bactericidal effect of tigecycline
against penicillin-susceptible and penicillin-resistant pneu-
mococci and some ESBL-producing Enterobacteriaceae was
reported by some studies.25,26 Our data indicate that tige-
cycline alone can pose a rapid bactericidal effect for clinical
V. vulnificus isolates.
Severe V. vulnificus infection, especially in immuno-
compromised patients, can manifest as bacteremia with or
without necrotizing fasciitis. In mice, the tigecycline Cmax
measured by bioassays was 0.98 mg/mL in serum and
1.65 mg/mL in uninfected thigh tissue, and both drug levels
are higher than the MIC90 for V. vulnificus. Accordingly,
tigecycline therapy could be reasonable for V. vulnificus
skin and soft-tissue infection, as reported in the litera-
ture.9,10 According to our study, the concentration of
0.12 mg/mL or 0.13 mg/mL is rapidly bactericidal for V.
vulnificus. However, tigecycline at currently recommended
dosages may be theoretically effective for septicemia due
to V. vulnificus, which is highly susceptible to tigecycline.
More clinical reports or investigations are warranted prior
to such a clinical practice.
Our in vivo data demonstrate that tigecycline mono-
therapy poses a similar killing effect as the combination of
minocycline and cefotaxime for experimental murine
infection with low inoculum of V. vulnificus. Furthermore,
the antibacterial effect of tigecycline was enhanced, if
combined with cefotaxime, for the treatment of high-
inoculum V. vulnificus infection. Tigecycline may be a po-
tential alternative to treat human V. vulnificus infection in
areas with limited access to old antibiotics. However, in
light of the species differences between mice and humans,
the extrapolation of animal data to clinical medicine should
be done with caution. More clinical trials involving tigecy-
cline monotherapy or combination regimens for invasive V.
vulnificus infections are warranted.
In our in vivo study, we use two different inoculums
1.25  105 and 1.25  106, which are higher than the LD50
(lethal dose, 50%) of this strain (LD50 approx. 10 CFU/
mouse) with around 104 and105 times. Therefore, even in
the deficiency of the immunocompromised mice to imitate
the immunocompromised status, the infection status seems
to be more severe than general condition. Such in vivoPlease cite this article in press as: Tang H-J, et al., In vitro and in v
Journal of Microbiology, Immunology and Infection (2016), http://dx.results demonstrate the combination of tigecycline and
cefotaxime can be used to treat severe V. vulnificus
infection in immunocompromised populations.
Previous reports have suggested that, in addition to
primary surgery, fluoroquinolones or third-generation
cephalosporins plus minocycline are the best option for
antibiotic treatment of necrotizing fasciitis caused by V.
vulnificus.8,27,28 Our major purpose was to investigate the
role of tigecycline instead of minocycline. Perhaps we can
perform another study to compare the effect of such an
agent with fluoroquinolones in the future.
In conclusion, the in vitro and animal studies indicate
that tigecycline alone or in combination with cefotaxime
might be as effective as the traditional combination of
minocycline and cefotaxime against V. vulnificus, and could
be an option for the treatment of invasive V. vulnificus
infections in areas without access to minocycline (for
injection).
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